Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 4.600
-0.010 (-0.22%)
Oct 23, 2026, 3:04 PM CST
SHE:002424 Revenue
Guizhou Bailing Group Pharmaceutical had revenue of 326.36M CNY in the quarter ending June 30, 2026, a decrease of -53.47%. This brings the company's total for the last twelve months to 2.56B, down -18.68% year-over-year. In the year 2025, Guizhou Bailing Group Pharmaceutical had annual revenue of 3.05B, down -20.31%. That makes Guizhou Bailing Group Pharmaceutical the 12,844th largest company in the world by revenue and 2,217th in China.
Revenue (ttm)
2.56B
Revenue Growth
-18.68%
P/S Ratio
2.66
Revenue / Employee
412.70K
Employees
5,715
Market Cap
6.28B
Revenue by Segment
- Industrial 2.49B 67.1%
- Commercial Business 1.13B 30.5%
- Medical Institutions 67.86M 1.8%
- Others 22.80M 0.6%
Fiscal year ended Dec 31, 2025 See the full SHE:002424 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | -776.76M | -20.31% |
| Dec 31, 2024 | 3.83B | -437.59M | -10.26% |
| Dec 31, 2023 | 4.26B | 722.84M | 20.42% |
| Jan 1, 2023 | 3.54B | 429.01M | 13.79% |
| Jan 1, 2022 | 3.11B | 23.24M | 0.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.